Trials / Completed
CompletedNCT02320474
Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Poitiers University Hospital · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a one-year pilot, interventional, prospective, single arm, non-randomized, multicentric (3 centers) controlled study that aims to evaluate the response of type 3 choroidal neovascularization to treatment by Aflibercept following a classic protocol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept |
Timeline
- Start date
- 2014-11-25
- Primary completion
- 2018-11-01
- Completion
- 2018-11-01
- First posted
- 2014-12-19
- Last updated
- 2019-03-08
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02320474. Inclusion in this directory is not an endorsement.